Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: February 27, 2006
Last updated: October 9, 2008
Last verified: October 2008
This study will investigate the incidence of influenza, disease and various possible downstream complications and hospitalizations or emergency room visits after routine annual vaccination of the elderly population with Fluarix™.

Condition Intervention
Biological: Fluarix

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: An Observational Study to Investigate the Incidence of Influenza, Downstream Complications of Influenza and Hospitalizations, in Elderly Subjects Vaccinated With GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Estimated Enrollment: 2000
Study Start Date: March 2006
Detailed Description:
This study will investigate the incidence of influenza, disease and various possible downstream complications, such as pneumonia, ischemic HD (unstable angina or MI), congestive heart failure, acute cerebrovascular disease, COPD exacerbation and hospitalizations or emergency room visits, and will evaluate the feasibility of health outcome surveillance and the validity of using questionnaires instruments, after routine annual vaccination of the elderly population with Fluarix™.

Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

All subjects must satisfy to the following criteria at study entry:

  • (1) A male or female age 65 years at the time of the first vaccination,
  • (2) Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g., return for follow-up visits, disease reporting by phone, and completion of Questionnaires) should be enrolled in the study
  • (3) Written informed consent obtained from the subject
  • (4) Availability to follow up by phone during the study period
  • (5) Subjects with residence status allowing free mixing with general community.

Exclusion Criteria

The subject must not be included in the study for:

  • (1) history of hypersensitivity to a previous dose of influenza vaccine
  • (2) history of allergy or reactions likely to be exacerbated by any component of the vaccine including egg, chicken protein, formaldehyde, thimerosal, gentamicin sulfate or sodium deoxycholate,
  • (3) use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00306982

Australia, New South Wales
GSK Investigational Site
Umina, New South Wales, Australia, 2257
Australia, Queensland
GSK Investigational Site
Kippa Ring, Queensland, Australia, 4021
GSK Investigational Site
South Brisbane, Queensland, Australia, 4101
Australia, Tasmania
GSK Investigational Site
Hobart, Tasmania, Australia
Australia, Victoria
GSK Investigational Site
Clayton, Victoria, Australia, 3168
GSK Investigational Site
Heidelberg Heights, Victoria, Australia, 3084
GSK Investigational Site
Parkville, Victoria, Australia, 3050
Australia, Western Australia
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
GSK Investigational Site
Woden, Australia, 2606
GSK Investigational Site
Curitiba/Paraná, Paraná, Brazil, 80810-050
GSK Investigational Site
São Paulo, Brazil, 04020050
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: Study Director, GSK Identifier: NCT00306982     History of Changes
Other Study ID Numbers: 106622 
Study First Received: February 27, 2006
Last Updated: October 9, 2008
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by GlaxoSmithKline:
Prophylaxis Influenza vaccine

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases processed this record on July 25, 2016